Analyze the Allegations
The Schall Law Firm is currently delving into claims concerning Ovid Therapeutics Inc. (NASDAQ: OVID). These claims revolve around potential violations of securities laws by Ovid. The focus of the investigation is on whether the company made false or misleading statements to investors.
Timeline of Events
On March 30, 2021, Ovid announced that Takeda Pharmaceutical Company Limited had obtained global rights to develop and commercialize its drug candidate soticlestat. However, on June 17, 2024, Ovid disclosed that Takeda’s studies in Dravet syndrome and Lennox-Gastaut syndrome narrowly missed their respective primary endpoints.
Join the Probe
Shareholders who have endured losses are urged to participate in the investigation. If you wish to join the inquiry, take action without delay.
Consultation with Experts
Reach out to Brian Schall of the Schall Law Firm in Los Angeles, California, to discuss your rights. The firm specializes in securities class action lawsuits and shareholder rights litigations.
Legal Disclaimer
The information presented in this release may fall under Attorney Advertising in some jurisdictions as per the applicable laws and ethical regulations.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20240801908975/en/